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Abstract
Background: We analysed kinetics of IL-7 and IL-15 levels in 70 patients given peripheral blood stem cells after
nonmyeloablative conditioning.
Methods: EDTA-anticoagulated plasma and serum samples were obtained before conditioning and about once per week
after transplantation until day 100. Samples were aliquoted and stored at 280uC within 3 hours after collection until
measurement of cytokines. IL-7 and IL-15 levels were measured by ELISAs.
Results: Median IL-7 plasma levels remained below 6 pg/L throughout the first 100 days, although IL-7 plasma levels were
significantly higher on days 7 (5.1 pg/mL, P = 0.002), 14 (5.2 pg/mL, P,0.001), and 28 (5.1 pg/mL, P = 0.03) (but not
thereafter) than before transplantation (median value of 3.8 pg/mL). Median IL-15 serum levels were significantly higher on
days 7 (12.5 pg/mL, P,0.001), 14 (10.5 pg/mL, P,0.001), and 28 (6.2 pg/mL, P,0.001) than before transplantation (median
value of 2.4 pg/mL). Importantly, IL-7 and IL-15 levels on days 7 or 14 after transplantation did not predict grade II–IV acute
GVHD.
Conclusions: These data suggest that IL-7 and IL-15 levels remain relatively low after nonmyeloablative transplantation, and
that IL-7 and IL-15 levels early after nonmyeloablative transplantation do not predict for acute GVHD.
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Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
following a high dose conditioning regimen has been the best
treatment option for many young patients with hematological
disorders. The antitumor activity of this approach is based not
only on high dose chemo-radiotherapy given in the conditioning
regimen but also on immune-mediated graft-versus-tumor effects
[1,2]. These observations are the basis of the development of allo-
HSCT following nonmyeloablative conditioning, in which erad-
ication of malignant cells depends on graft-versus-tumor effects [3–
6].
T-cell recovery after allo-HSCT following high-dose condition-
ing depends on both homeostatic peripheral expansion (HPE) of
donor T cells contained in the graft, and T cell neo-production
from donor hematopoietic stem cells (thymo-dependent pathway)
[7–15]. In young patients given myeloablative allo-HSCT, most
circulating T cells during the first months following HSCT are the
progeny of T cells infused with the grafts [16], while neogeneration
of T cells by the thymus plays an increasing role in reconstituting
the T cell pool beyond day 100 after allo-HSCT [17–22]. Since
HPE allow the expansion of both NK cells and non-tolerant T
cells, it is generally accepted that HPE is one of the driving force of
graft-versus-tumor effects.
Several studies have demonstrated that IL-7 and IL-15 are the
main driving forces of HPE after allo-HSCT following high-dose
conditioning [7,23]. IL-7 is a c-common chain cytokine that is
secreted by stromal cells from multiple organs including thymus,
bone marrow, and lymphoid organs. IL-7 is required for human T
cell development since mutations in the IL-7 receptor alpha can
lead to severe combined immunodeficiency [24]. Administration
of IL-7 has been shown to dramatically increase peripheral T cell
numbers, primarily through augmentation of HPE [25–31]. IL-15
is another c-common chain cytokine secreted by antigen-
presenting cells, bone marrow stroma, thymic epithelium, and
epithelial cells in the kidney, skin, and intestines [32]. IL-15 plays
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an important role in the development and function of NK cells,
and of NK/T cells, and is required for optimal proliferation of
CD8+ T cells and for homeostatic proliferation of CD8+ memory
T cells [33–39].
While high-dose conditioning regimens typically induce a
profound lymphodepletion, progressive replacement of host-
derived T cells by donor-derived T cells is the rule after
nonmyeloablative conditioning [40,41]. This prompted us to
analyze the kinetics of IL-7 and IL-15 blood levels after allo-
HSCT following a nonmyeloablative conditioning with the aim of
determining whether there is a rational for boosting HPE and
perhaps graft-versus-tumor effects in patients with high risk disease




Data from 70 patients transplanted between March 2007 and
April 2011 at the University of Lie`ge were included in the study
(Table 1). All patients were given G-CSF-mobilized peripheral
blood stem cells (PBSC) after low-dose [2 Gy (n = 60), or 4 Gy
(n = 10)] total body irradiation (TBI)-based nonmyeloablative
regimen. Twenty-three nonmyeloablative recipients who were
given PBSC from HLA-mismatched unrelated donors were co-
transplanted with third party mesenchymal stromal cells (MSCs) as
a potential way to prevent severe GVHD [42]. Further, 3
nonmyeloablative recipients were included in a double blind
randomized study assessing the impact of MSC co-transplantation
on transplantation outcomes. No patient was given in-vivo T cell
depletion.
Ethics
Written informed consent was obtained from each patient to
undergo allo-HSCT and to collect, store and analyze blood
samples for research purposes. The Ethics Committee of the
University of Lie`ge (‘‘Comite´ d’Ethique Hospitalo-Facultaire
Universitaire de Lie`ge’’) approved the consent form as well as
the current research study protocol (protocol #B707201112193).
Clinical Management
The clinical management has been performed as previously
reported [43,44]. Chimerism levels among peripheral T-cells were
generally measured with PCR-based analysis of polymorphic
microsatellite regions (AmpFlSTRH IdentifilerH, Applied Biosys-
tems, Lennik, Belgium) [43]. CD3 (T-cell) selection was carried
out with the RosetteSepR human T-cell enrichment kit (StemCell
Technologies, Vancouver, Canada) [43,44].
Cytokines Levels
EDTA-anticoagulated plasma and serum samples were ob-
tained before conditioning and about once time per week after
transplantation until day 100. Samples were aliquoted and stored
at 280uC within 3 hours after collection until measurement of
cytokines. Kinetic courses of IL-7 production in plasma samples
were evaluated before conditioning and approximately at days 7,
14, 28, 40, 60, 80 and 100 after allo-HSCT. IL-15 serum sample
levels were assessed before conditioning and approximately at days
7, 14 and 28 after allo-HSCT. IL-7 and IL-15 levels were
measured by ELISAs following the manufacturer’s protocol (High
sensitivity IL-7 and IL-15 quantikine, R&D Systems, Minneapolis,
MN, USA). The standard curve ranges for IL7 were 0.25 to
16 pg/mL, and the minimal detectable dose was,0.1 pg/mL. No
patient had IL-7 levels below this threshold in the current study.
The standard curve ranges for IL15 were 3.9 to 250 pg/mL, and
the minimal detectable dose was ,2 pg/mL. Il-15 levels were
between 0 and 2 pg/mL in our study in 15 patients before
transplantation, in no patient on days 7 and 14, and in 1 patient
on day 28. No sample dilution was performed for IL-15 assay. For
IL-7 analysis, samples were diluted twice. Patient samples whose
cytokine level were out of standard curve range, were re-assessed
after dilution.
Immune Recovery
Immune recovery was prospectively assessed as previously
described [43,44]. Briefly, patients’ peripheral white blood cells
were phenotyped using 4 color flow cytometry after treatment with
a red blood cell lyzing solution. The following antibodies were
used: CD3-ECD (Beckman Coulter, Iotest #A07748); CD4-V450
(Becton Dickinson Horizon #560345); CD8-FITC (Beckman
Coulter Iotest #A07756); CD56-PC7 (Beckman Coulter Iotest
#A21692); CD45RA-PE (Dako #R7086). The percentage of
positive cells was calculated relative to total nucleated cells, after
subtraction of non-specific staining. Absolute counts were obtained
by multiplying the percentages of positive cells by the white blood
cell counts (XE-5000 hematology analyzer, Sysmex, Kobe, Japan).
Absolute lymphocytes counts (ALC) were measured directly by the
XE-5000 analyzer or after microscopic review of the blood smears
when the automated differential was flagged. Absolute white blood
cell counts were used instead of ALC when white blood cell counts
were below 150 cells 6109/L.
Statistical Analyses
The Mann Whitney test was used to compare counts of
lymphocyte subset and cytokine levels in patients given grafts after
2 Gy or 4 Gy TBI. The Wilcoxon matched pair test was used to
compare cytokines levels before and at various time points after
transplantation. Generalized linear mixed models were used to
analyze factors affecting immune recovery and cytokine levels after
transplantation. Factors included in the models included : (1) dose
of TBI (2 Gy vs 4 Gy), MSC infusion or not, number of days after
allo-HSCT, number of CD3+ cells transplanted, donor type
(related vs unrelated), patient age, and donor age for analyses
examining lymphocyte counts; (2) dose of TBI (2 Gy vs 4 Gy),
MSC infusion or not, grade II–IV acute GVHD the first 100 days
after transplantation, number of CD3+ cells transplanted, donor
type (related vs unrelated), patient age, and donor age, and either
IL-7 or IL-15 levels on days 7–14 (median) for analyses examining
lymphocyte count increments from days 14–28 (median) to days
80–100 (median); and (3) number of days after allo-HSCT,
number of CD3+ cells transplanted, donor type (related vs
unrelated), dose of TBI (2 Gy vs 4 Gy), ALC, CRP levels, donor
and patient ages, and MSC infusion or not, for analyses of
cytokine levels. Incidences of acute GVHD according to the
cytokines levels were assessed using cumulative incidence methods.
A Cox model was constructed for determining potential factors
associated with the occurrence of grade II–IV acute GVHD the
first 200 days after transplantation. Factors included in the model
included median day 7 and day 14 IL-7 levels, median day 7 and
day 14 IL-15 levels, dose of TBI (2 Gy vs 4 Gy), donor type
(related vs unrelated), female donor to male recipient versus other
gender combination, MSC infusion or not, patient age, and donor
age. Spearman’s correlation was used to examine the relationship
between parameters. Statistical analyses were carried out with
Graphpad Prism (Graphpad Software, San Diego, CA) and SAS
version 9.2 for Windows (SAS Institute, Cary, NC, USA).
IL-7 and IL-15 after Allo-HSCT
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Results
Immune Recovery
Median ALC count on day 0 was 110 (range, 10–5440) cells/
ml, demonstrating the persistence of recipient T cells at the time
of transplantation. While median CD8+ T cell levels reached
the lower limit of normal values from day 60 after transplan-
tation, median CD4+ T cell (including naı¨ve CD4+ T cells)
remained below the lower limit of normal values the first 6
months after transplantation (Figure 1). No significant difference
of T cell subset counts were observed between 2 Gy and 4 Gy
TBI regimen. Using generalized linear mixed models taking into
consideration data from day 14, 28, 40, 60, 80 and 100 for
each patient, counts of CD3+ T cells (P,0.001), CD8+ T cells
(P,0.001), CD4+ T cells (P = 0.024), NK cells (P,0.001) and
NK/T cells (P,0.001) increased over time but not those of
naı¨ve CD4+ T cells (P = 0.13). Further, high numbers of
transplanted CD3+ T cells were associated with higher counts
CD3+ T cells (P = 0.009), CD8+ T cells (P = 0.003), and CD4+
T cells (P = 0.0099), while high donor age was associated with
lower counts of CD3+ T cells (P = 0.04), CD4+ T cells
(P = 0.05), and naı¨ve CD4+ T cells (P = 0.021). There was no
significant association between MSC administration and lym-
phocyte subset counts after transplantation.
IL-7 Plasma Levels
Median IL-7 plasma levels remained below 6 pg/L throughout
the first 100 days (the upper limit of normal range being 9.2 pg/
mL (Quantikine HS catalog number HS750)), although IL-7
plasma levels were significantly higher on days 7 (5.1 pg/mL,
P = 0.002), 14 (5.2 pg/mL, P,0.0001) and 28 (5.1 pg/mL,
P = 0.03) (but not thereafter) than before transplantation (median
value of 3.8 pg/mL) (Figure 1G). Using generalized linear mixed
models, low number of transplanted CD3+ T cells (P = 0.001), low
ALC level the day of IL-7 assessment (P,0.0001), high donor age
(P = 0.003), having received PBSC from unrelated donors
(p = 0.006), and high level of CRP the day of IL-7 assessment
(P = 0.033) were associated with high levels of IL-7 (Table 2).
Il-15 Serum Levels
Median IL-15 serum levels were significantly higher on days 7
(12.5 pg/mL, P,0.001), 14 (10.5 pg/mL, P,0.001) and 28
(6.2 pg/mL, P,0.001) than before transplantation (median value
of 2.4 pg/mL) (Figure 1H). IL-15 levels on day 7 and 14 were
significantly higher in 4 Gy than 2 Gy TBI. Using generalized
linear mixed models, conditioning with 4 versus 2 Gy TBI
(P = 0.002), having received PBSC from unrelated donors
(P = 0.001), low ALC level the day of IL-15 assessment
(P,0.001), and high level of CRP the day of IL-15 assessment
Table 1. Patients’ characteristics.
Nonmyeloablative conditioning (n =70)
Median age (range) 50 (16–73)
Gender (male/female) 48/22
Diagnostic (# of patients)
Acute myeloid leukemia in CR 21
Acute lymphoblastic leukemia in CR 4
Chronic myeloid leukemia 1
Chronic lymphocytic leukemia 6
Lymphoma 16
Myelodysplatic syndrome/myeloproliferative disorder 9
Multiple myeloma 13
Donor (# of patients)
Sibling 13
Unrelated 57
Conditioning regimen (# of patients)
TBI 2 Gy 1
Fludarabine 90 mg/m2+TBI 2 Gy 59
Fludarabine 90 mg/m2+TBI 4 Gy 10






Graft composition; median (range) x 106/kg
CD34 5.4 (1.1–14.5)
CD3 314 (92–1216)
*double blind randomized study: The information of which of these 3 patients (if any) have been given MSC has been given by the director of the Cell Laboratory only
to LS (the statistician); TBI, total body irradiation; MMF, mycophenolate mofetil.
doi:10.1371/journal.pone.0055876.t001
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(P = 0.006) were each associated with high IL-15 levels on days 7
and 14 after allo-HSCT (Table 2).
Correlation between IL-7 and IL-15 Levels and
Lymphocyte Subset Counts on Days 14 or 28 after allo-
HSCT
Day 14 IL-7 levels inversely correlated with day 14 counts of
CD3+ T cells (R =20.46, P = 0.002; Figure 2A), CD8+ T cells
(R =20.41, P = 0.006), CD4+ T cells (R =20.44, P = 0.004), and
memory CD4+ T cells (R =20.45, P = 0.003), but not with counts
of naı¨ve CD4+ T cells (R =20.28, P = 0.07), NK/T cells
(R =20.04, P = 0.8) nor NK cells (R =20.14, P = 0.4). There
was a weak association between day 14 IL-7 and IL-15 levels
(R = 0.27, P = 0.049). Further, day 14 IL-15 levels correlated with
day 14 counts of NK cells (R =20.32, P = 0.039; Figure 2B) and
of NK/T cells (R =20.32, P = 0.037), but not with those of other
T cell subsets.
Day 28 IL-7 levels inversely correlated with day 28 counts of
CD3+ T cells (R =20.47, P,0.001; Figure 2A), CD8+ T cells
(R =20.41, P = 0.002), CD4+ T cells (R =20.39, P = 0.002),
naı¨ve CD4+ T cells (R =20.40, P = 0.002), and memory CD4+ T
cells (R =20.38, P = 0.004), but not with counts of NK/T cells
(R =20.17, P = 0.2), nor NK cells (R =20.02, P = 0.9), nor with
day-28 donor T cell chimerism levels (R = 0.0, P = 0.95). There
was no significant association either between day 28 IL-7 and IL-
15 levels (R = 0.07, P = 0.6). Further, day 28 IL-15 levels
correlated with day 28 counts of NK cells (R =20.32,
P = 0.015; Figure 2B) but not with those of T cell subsets, nor
with day-28 donor T cell chimerism levels (R = 0.14, P = 0.29).
To further assess the potential association between early IL-7 or
IL-15 levels on immune recovery, we analysed whether there was
a relationship between median cytokine levels on days 7 and 14
and the difference of lymphocyte subset counts between days 80–
100 (median) and days 14–28 (median). Interestingly, in multi-
variate analyses, early IL-7 levels did not correlate with any
lymphocyte subset increment from days 14–28 to day 80–100 after
transplantation, while high IL-15 levels early after transplantation
correlated with a lower increment of NK cells over time (P = 0.04).
IL-7 and IL-15 Levels did not Predict for Subsequent
Acute GVHD
The 180-day cumulative incidence of grade II–IV acute GVHD
was 30%, a rate similar to what has been observed by other group
of investigators using similar conditioning regimen [45]. As shown
in the Figure 3, no statistically significant association between
cytokines levels on days 7 or 14 after transplantation and
occurrence of grade II–IV acute GVHD were observed.
Specifically, the 180-day cumulative incidence of grade II–IV
acute GVHD was 29% in patients with day 7 IL-7 levels.median
(5.1 pg/mL) versus 20% in patients with day 7 IL-7 levels #
median (P = 0.38) (Figure 3A). Similarly, the 180-day cumulative
Figure 1. Median ALC (A), median MNC-subset cell counts (B–F), and median IL-7 (G) and IL-15 (H) after allogeneic hematopoietic
cell transplantation following 2 Gy (continuous line) or 4 Gy (broken line) total body irradiation. The error bars shows the 25th and 75th
percentiles. For ALC and MNC-subset, horizontal lines show the medians and the grey square the limit of normal value (if non truncated) in 47 healthy
volunteer donors; for IL-7, horizontal line shows the medians and the grey square the limit of normal value according to the manufacturer brochure.
*, P,0.05; **, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0055876.g001
Table 2. Multivariable analyses of factors affecting cytokines
levels on days 7 and 14 after allo-HSCT.
Factor(s) associated with higher levels*,{
IL-7 - Low ALC on day 7 or 14 (P,0.001).
- Low # of transplanted T cells (CD3+) (P = 0.001).
- High CRP levels on day 7 or 14 (P = 0.033).
- Unrelated donors (P = 0.006).
- High donor age (P = 0.003).
IL-15 - 4 vs 2 Gy TBI (P = 0.002).
- Unrelated donors (P = 0.001).
- High CRP levels on day 7 or 14 (P = 0.006).
- Low ALC on day 7 or 14 (P,0.001).
*Other factors assessed were number of days after allo-HSCT, patient age, and
mesenchymal stromal cells infusion or not;
{P values were determined according to generalized linear mixed models;
TBI, total body irradiation.
doi:10.1371/journal.pone.0055876.t002
Figure 2. Correlation between CD3+ T cell counts and IL-7
levels on day 14 (black circles and continuous line) and on day
28 (open triangles and broken lines) after transplantation (A).
Correlation between NK cell counts and IL-15 levels on day 14 (black
circles and continuous line) and on day 28 (open triangles and broken
lines) after transplantation (B).
doi:10.1371/journal.pone.0055876.g002
IL-7 and IL-15 after Allo-HSCT
PLOS ONE | www.plosone.org 5 February 2013 | Volume 8 | Issue 2 | e55876
incidence of grade II–IV acute GVHD was 19% in patients with
day 14 IL-7 levels.median (5.2 pg/mL) versus 37% in patients
with day 14 IL-7 levels # median (P = 0.18) (Figure 3B).
The 180-day cumulative incidence of grade II–IV acute GVHD
was 24% in patients with day 7 IL-15 levels.median (12.5 pg/
mL) versus 28% in patients with day 7 IL-15 levels # median
(P = 0.8) (Figure 3C). Similarly, the 180-day cumulative incidence
of grade II–IV acute GVHD was 25% in patients with day 14 IL-
15 levels.median (10.5 pg/mL) versus 33% in patients with day
14 IL-15 levels # median (P = 0.8) (Figure 3D).
Finally, in a multivariate Cox model, neither median IL-7 levels
(P = 0.17 with a trend for an inverse correlation) on days 7–14 nor
median IL-15 levels (P = 0.21 with a trend for a positive
correlation) on days 7–14 correlated with occurrence of grade
II–IV acute GVHD the first 200 days after transplantation.
Similarly, the use of MSC was not associated with decreased
incidence of grade II–IV acute GVHD. This could be explained
by the fact that all 23 MSC recipients versus of 9 of the remaining
49 patients (18%) received PBSC from HLA-mismatched donors.
None of the other factors tested (dose of TBI, donor type, female
donor to male recipient versus other gender combination, patient
age, and donor age) were significantly associated with the
incidence of grade II–IV acute GVHD in the current study.
IL-15 Levels did not Predict for Subsequent Relapse/
Progression
Given that a previous publication showed an association
between high IL-15 levels and low risk of relapse/progression
[46], we compared the cumulative incidence of relapse/progres-
sion according to IL-15 levels 14 days after transplantation in our
cohort of patients. The 6-month and 1-year cumulative incidences
of relapse/progression were 29% and 32%, respectively, in
patients with day 14 IL-15 levels.median (10.5 pg/mL) versus
37% and 46%, respectively, in patients with day 14 IL-15 levels #
median (P = 0.57).
Discussion
Following allo-HSCT, eradication of residual tumor cells
depends in part (in case of high-dose conditioning) or mainly (in
case of nonmyeloablative conditioning) on immune-mediated
graft-versus-tumor effects [1,2,4]. Prior studies have demonstrated
a close relationship between T cell reconstitution and graft-versus-
tumor effects after allo-HSCT [4,14,47–49]. Given that HPE
allows the expansion of potentially alloreactive T cell clones, it has
been generally accepted that HPE plays a major role in graft-
versus-tumor effects, but could also cause or favor acute GVHD.
Figure 3. Cumulative incidence of grade II–IV acute GVHD according to day 7 IL-7 plasma levels among nonmyeloablative
recipients (P =0.4) (A). Cumulative incidence of grade II–IV acute GVHD according to day 14 IL-7 plasma levels among nonmyeloablative recipients
(P = 0.18) (B). Cumulative incidence of grade II–IV acute GVHD according to day 7 IL-15 serum levels among nonmyeloablative recipients (P = 0.8) (C).
Cumulative incidence of grade II–IV acute GVHD according to day 14 IL-15 serum levels among nonmyeloablative recipients (P = 0.6) (D).
doi:10.1371/journal.pone.0055876.g003
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This prompted us to investigate the kinetics of IL-7 and IL-15
levels in a cohort of 70 patients given grafts after truly
nonmyeloablative conditioning.
First, patients given grafts after nonmyeloablative conditioning
had only a modest (,2 fold) increase of IL-7 levels after
transplantation (contrarily to what we observed in another cohort
of patients given grafts after myeloablative conditioning [50]), that
persisted up to day 21. This is probably due to the fact that
nonmyeloablative patients experienced relatively mild lymphope-
nia (and thus continue to consume the IL-7 produced by stromal
cells) as demonstrated by the persistence of median ALC counts of
110 cells/mL at the time of transplantation. Although the first T
cell chimerism assessment in current patient was usually around
day 28 after HSCT, a prior study analyzing data from patients
given similar conditioning regimen demonstrated that a median of
50 CD3+ T cells of recipient origin/mL persisted on day 14 after
HSCT [40]. Further, as observed by other groups of investigators
[46,51,52], there was a strong inverse correlation between IL-7
levels and absolute lymphocyte counts [46,52], as well as a strong
inverse correlation between IL-7 levels and T cell subsets on days
14 and 28 after transplantation. Other factors associated with IL-7
levels included high CRP levels, and low numbers of transplanted
T cells. Levels of IL-7 in current nonmyeloablative recipients
where lower to what was observed by Thiant et al. in a cohort of 45
patients given grafts after fludarabine +2 Gy TBI (n = 18) or more
intense but still reduced-intensity conditioning (n = 27) [52], and
where much lower than what was observed by Dean et al. in
patients given grafts after sequential chemotherapy followed by a
chemotherapy/fludarabine-based reduced-intensity conditioning
[53]. This apparent discrepancy is probably explained the fact
than median ALC counts on day 0 were 110 (range, 10–5440)
cells/ml in current patient versus 0 (range, 0–322) cells/mL in the
Dean et al. study, while median counts of CD3+ T cells were 0
(range, 0–1900) cells/mL at the time of transplantation in Thiant
et al. study.
Il-15 levels were lower in nonmyeloablative patients conditioned
with 2 Gy TBI than in those conditioned with 4 Gy TBI,
demonstrating that the release of IL-15 was proportional to the
intensity of the conditioning regimen. As observed by Thiant et al.
[46,52], there was a correlation between IL-7 and IL-15 levels on
day 14 (but not on day 28) after transplantation, and an inverse
correlation between IL-15 levels and NK cell counts. Other factors
affecting IL-15 levels included high CRP levels.
Several observations demonstrate that immune recovery
depended mainly on HPE the first year after nonmyeloablative
conditioning regimen in current patients. Firstly, there was a
strong correlation between the number of infused T cells and high
counts of CD4+ and CD8+ T cells, as previously observed [43,54].
Secondly, thymic function was minimal during the first 100 days
after allo-HSCT given that levels of naı¨ve CD4+ T cells did not
significantly increase the first 100 days after transplantation
despite that some naı¨ve T cells can undergo HPE and keep their
naı¨ve phenotype. Third, there was a correlation between high
donor age and low counts of CD3+ T cells (P = 0.04), CD4+ T cells
(P = 0.05), and naı¨ve CD4+ T cells (P = 0.021), as previously
observed in patients given grafts after nonmyeloablative condi-
tioning [55]. Despite that, we failed to find any significant
association between IL-7 and/or IL-15 levels early after
transplantation and increment of T cell subset counts from days
14–28 to day 80–100, even after adjusting for potentially
confounding cofactors.
A number of previous studies have demonstrated that high
levels of IL-7 [46,52,53] and/or IL-15 [46,52] early after
transplantation correlated with subsequent occurrence of grade
II–IV acute GVHD, while others study failed to find such an
association [51,56]. The largest study including data from 153
consecutive allogeneic transplant recipients given grafts after high-
dose conditioning and ATG observed no correlation between IL-7
levels early after transplantation and acute GVHD, while,
interestingly, there was an inverse correlation between IL-15
levels early after transplantation and grade II–IV acute GVHD
[57]. Further, a recent study demonstrated that administration of
IL-7 after allogeneic T cell-depleted transplantation in humans did
not increase acute GVHD [58]. In the current study, we did not
observe any association between levels of IL-7 or IL-15 early after
allo-HSCT and grade II–IV acute GVHD. The same was true
after adjusting the analyses for potentially confounding cofactors.
Differences in postgrafting immunosuppression might be the cause
for these apparent discrepancies between studies. As example, it
has been shown that tacrolimus (given in patients included in the
current study) decreased T cell proliferation induced by IL-7 [59],
and tacrolimus levels were kept high in our patients the first weeks
after transplantation (median 18.6, 16.4, 14.9 and 14.3 mg/L on
days 0, 7, 14 and 21 after transplantation, respectively) probably
explaining the low relatively incidence of acute GVHD observed
[60].
In summary, these data suggest that IL-7 and IL-15 levels
remain relatively low after nonmyeloablative transplantation, and
that IL-7 and IL-15 levels early after nonmyeloablative transplan-
tation do not predict for acute GVHD.
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